Oppenheimer downgraded Spruce Biosciences (SPRB) to Perform from Outperform without a price target The company announced disappointing topline results from both of its ongoing trials of tildacerfont, the analyst tells investors in a research note. The firm awaits clarity on next steps with Spruce winding down both trials and prioritizing cash conservation as it evaluates strategic alternatives.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SPRB:
- Spruce Biosciences downgraded to Market Perform from Outperform at JMP
- Spruce Biosciences Inc trading resumes
- Spruce Biosciences Inc trading halted, news pending
- Spruce Biosciences CAHmelia-204 study did not achieve primary efficacy endpoint
- Spruce Biosciences Faces Nasdaq Delisting Threat: Can a Reverse Stock Split Save Its Market Presence?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
